Ivera Medical gains licence to BD IV technology
This article was originally published in Clinica
Executive Summary
Medical device manufacturer Ivera Medical has secured exclusive worldwide rights to patents covering intravenous port protector technology belonging to BD (Becton Dickinson). Ivera has gained a licence for issued and pending patents covering technology designed to reduce the potential for healthcare-acquired bloodstream infections. Ivera vice-president of marketing and sales Jack Saladow said that this deal would broaden the San Diego, California company’s existing patent applications and remove any potential patent issues between the two firms. No financial details of the deal were disclosed. Healthcare-acquired bloodstream infections are said to cost the US healthcare system more than $5bn each year.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals